Movement Alert｜HANSOH PHARMA Rises 3.47% in Regular Trading, New Drug Clinical Approval and Pipeline Milestones Continue to Drive Momentum

Market Focus08-11

On August 11, HANSOH PHARMA rose 3.47% in regular trading, trading at HK$36.0 per share, with turnover of approximately HK$74.44 million. The stock continued its upward trajectory fueled by a series of recent pipeline catalysts.

On the news front, the company announced on August 6 that its proprietary Class 1 new drug HS-10582 tablets received clinical trial approval from China's National Medical Products Administration for the treatment of adult primary hypercholesterolemia and mixed dyslipidemia, adding a new candidate to its cardiovascular-metabolic pipeline. Additionally, CLSA maintained its Outperform rating and raised the target price to HK$42, projecting five new drug approvals next year including B7-H3 ADC, Olatorepatide, c-MET, and RET inhibitors, forecasting revenue growth of 14%, 10%, and 14% for the next three years respectively.

Further supporting sentiment, the company's core ADC candidate HS-20093 recently achieved primary endpoints in Phase 3 trials for both osteosarcoma and small cell lung cancer, with biologics license applications under preparation. The company's interim results are scheduled for disclosure on August 26.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1141071899?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-11 09:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141071899","market":"hk","top_or_hot":-1,"title":"Movement Alert｜HANSOH PHARMA Rises 3.47% in Regular Trading, New Drug Clinical Approval and Pipeline Milestones Continue to Drive Momentum","media":"Market Focus","content":"<p><p>On August 11, HANSOH PHARMA rose 3.47% in regular trading, trading at HK$36.0 per share, with turnover of approximately HK$74.44 million. The stock continued its upward trajectory fueled by a series of recent pipeline catalysts.</p><p>On the news front, the company announced on August 6 that its proprietary Class 1 new drug HS-10582 tablets received clinical trial approval from China's National Medical Products Administration for the treatment of adult primary hypercholesterolemia and mixed dyslipidemia, adding a new candidate to its cardiovascular-metabolic pipeline. Additionally, CLSA maintained its Outperform rating and raised the target price to HK$42, projecting five new drug approvals next year including B7-H3 ADC, Olatorepatide, c-MET, and RET inhibitors, forecasting revenue growth of 14%, 10%, and 14% for the next three years respectively.</p><p>Further supporting sentiment, the company's core ADC candidate HS-20093 recently achieved primary endpoints in Phase 3 trials for both osteosarcoma and small cell lung cancer, with biologics license applications under preparation. The company's interim results are scheduled for disclosure on August 26.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜HANSOH PHARMA Rises 3.47% in Regular Trading, New Drug Clinical Approval and Pipeline Milestones Continue to Drive Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜HANSOH PHARMA Rises 3.47% in Regular Trading, New Drug Clinical Approval and Pipeline Milestones Continue to Drive Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-11 09:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 11, HANSOH PHARMA rose 3.47% in regular trading, trading at HK$36.0 per share, with turnover of approximately HK$74.44 million. The stock continued its upward trajectory fueled by a series of recent pipeline catalysts.</p><p>On the news front, the company announced on August 6 that its proprietary Class 1 new drug HS-10582 tablets received clinical trial approval from China's National Medical Products Administration for the treatment of adult primary hypercholesterolemia and mixed dyslipidemia, adding a new candidate to its cardiovascular-metabolic pipeline. Additionally, CLSA maintained its Outperform rating and raised the target price to HK$42, projecting five new drug approvals next year including B7-H3 ADC, Olatorepatide, c-MET, and RET inhibitors, forecasting revenue growth of 14%, 10%, and 14% for the next three years respectively.</p><p>Further supporting sentiment, the company's core ADC candidate HS-20093 recently achieved primary endpoints in Phase 3 trials for both osteosarcoma and small cell lung cancer, with biologics license applications under preparation. The company's interim results are scheduled for disclosure on August 26.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1141071899","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141071899","pubTimestamp":1786412068,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 11, HANSOH PHARMA rose 3.47% in regular trading, trading at HK$36.0 per share, with turnover of approximately HK$74.44 million. The stock continued its upward trajectory fueled by a series...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"动向提醒|豪森医药常规交易涨3.47%，新药临床获批及管线里程碑持续推动动能","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"On August 11, HANSOH PHARMA rose 3.47% in regular trading, trading at HK$36.0 per share, with turnover of approximately HK$74.44 million. The stock continued its upward trajectory fueled by a series of recent pipeline catalysts.On the news front, the company announced on August 6 that its proprietary Class 1 new drug HS-10582 tablets received clinical trial approval from China's National Medical Products Administration for the treatment of adult primary hypercholesterolemia and mixed dyslipidemia, adding a new candidate to its cardiovascular-metabolic pipeline. Additionally, CLSA maintained its Outperform rating and raised the target price to HK$42, projecting five new drug approvals next year including B7-H3 ADC, Olatorepatide, c-MET, and RET inhibitors, forecasting revenue growth of 14%, 10%, and 14% for the next three years respectively.Further supporting sentiment, the company's core ADC candidate HS-20093 recently achieved primary endpoints in Phase 3 trials for both osteosarcoma and small cell lung cancer, with biologics license applications under preparation. The company's interim results are scheduled for disclosure on August 26.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141071899","isCrawlerRequest":true}